Platelet-function analyzer closure times indicate shear stress-induced hemostatic abnormalities in patients with aortic valve stenosis and correlate with perioperative transfusion requirements
Restricted accessResearch articleFirst published online May, 2010
Platelet-function analyzer closure times indicate shear stress-induced hemostatic abnormalities in patients with aortic valve stenosis and correlate with perioperative transfusion requirements
Background: Shear stress-induced hemostatic abnormalities are highly prevalent in patients with aortic valve stenosis. In this study, we determined closure times with a platelet-function analyzer (PFA-100, Dade Behring, Marburg, Germany) in patients admitted for aortic valve replacement to assess the correlation with the severity of aortic valve stenosis, blood loss, perioperative transfusion requirements, and need for re-thoracotomy.
Patients and Methods: Fifty consecutive patients (mean age [± SD] 68 ± 9 years) were enrolled. Closure times of epinephrin/collagen and adenosine diphosphate (ADP)/collagen cartridges were determined at least ten days after discontinuation of antiplatelet medication and compared to those of healthy control subjects without medication.
Results: Closure times of epinephrin/collagen (210 ± 69 sec vs. 140 ± 50 sec, p < 0.0001) and ADP/collagen (145 ± 58 sec vs. 108 ± 45 sec, p < 0.0001) cartridges were prolonged in patients with aortic valve stenosis. Intraoperative transfusion of red blood cell units was associated with the closure times of epinephrin/collagen (r = 0.28, p = 0.04) and ADP/ collagen cartridges (r = 0.28, p = 0.04). Total transfusion of red blood cell units was associated with ADP/ collagen closure times (r = 0.31, p = 0.02), but not epinephrin/collagen closure times (r = 0.26, p = 0.07). No significant association of closure times with intraoperative, postoperative and total transfusion of fresh frozen plasma units was observed.
Conclusions: Prolongation of closure times determined with a platelet-function analyzer is highly prevalent in patients with aortic valve stenosis and appears to reflect shear stress-induced hemostatic abnormalities. Since prolonged closure times are associated with increased perioperative transfusion of red blood cell units, the assay could significantly contribute to the identification of individuals at risk.
Sucker C., Stockschlader M., Zotz RB, Scharf REAcquired von Willebrand Syndrome. Dtsch Med Wschr2004; 129: 1581-1585.
2.
Sucker C.The Heyde Syndrome: proposal for a unifying concept explaining the association of aortic valve stenosis, gastrointestinal angiodysplasia and bleeding. Int J Cardiol2007 Jan 31; 115(1): 77-78. Epub 2006 Jun 5.
3.
Warkentin TE , Moore JC, Morgan DGAortic stenosis and bleeding gastrointestinal angiodysplasia: is acquired von Willebrand syndrome the link ?Lancet1992; 240: 35-37.
4.
Fressinaud E. , Veyradier A., Truchaud F., et al. Screening for von Willebrand disease with a new analyzer using high shear stress: a study of 60 cases. Blood1998; 91: 1325-1331.
Harrison O., Robinson M., Liesner R., et al. The PFA-100: a potential rapid screening tool for the assessment of platelet dysfunction. Clin Lab Haematol2002; 24: 225-232.
7.
Warkentin, TE , Moore, JC, Anand, SS, Lonn EM, Morgan DGGastrointestinal bleeding, angiodysplasia, cardiovascular disease, and acquired von Willebrand syndrome. Transfus Med Rev2003; 17: 272-286.
8.
Anderson RP, McGrath K., Street A.Reversal of aortic stenosis, bleeding gastrointestinal angiodysplasia, and von Willebrand syndrome by aortic valve replacement. Lancet1996; 347: 690.
9.
Olsson M., Hultcrantz R., Schulman S., Wallgren E.Acquired platelet dysfunction may be an aetiologic factor in Heyde’s syndrome--normalization of bleeding time after aortic valve replacement. J Intern Med2002; 252: 516-523.
10.
Sucker C., Feindt P., Zotz RB, Stockschlader M., Scharf REFunctional von Willebrand Factor assays are not predictive for the absence of highest-molecular weight von Willebrand Factor multimers in patients with aortic valve stenosis. Thromb Haemost2005 ; 94: 465-466.
11.
Sucker C., Feindt P., Scharf REAortic stenosis, von Willebrand factor, and bleeding. N Engl J Med2003; 349: 1773-1774.
12.
Sucker C., Feindt P., Stockschlader M., Zotz RB, Scharf REAcquired alterations of von Willebrand Factor in aortic valve stenosis: rather a laboratory finding than a cause of clinically relevant bleeding. Abstracts of the American Society of Hematology Meeting. Blood2003; 102(11): 117.
13.
Vincentelli A., Susen S., Le Tourneau T., et al. Acquired von Willebrand syndrome in aortic stenosis. N Engl J Med2003; 349: 343-349.
14.
Abaci A., Caliskan M., Bayram F., et al. A new definition of aspirin non-responsiveness by platelet function analyzer-100™ and its predictors. Platelets2006; 17: 7-13.
15.
Feuring M., Schultz A., Losel R., Wehling M.Monitoring acetylsalicylic acid effects with the platelet function analyzer PFA-100. Semin Thromb Hemost2005; 31: 411-415.
